Concepedia

Publication | Open Access

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

DOIFull Paper Access

2.8K

Citations

20

References

2018

Year

David Adams, Alejandra González‐Duarte, William O’Riordan, Chih‐Chao Yang, Mitsuharu Ueda, Arnt V. Kristen, Ivailo Tournev, Hartmut Schmidt, Teresa Coelho, John L. Berk,
New England Journal of Medicine

Abstract

In this trial, patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis. (Funded by Alnylam Pharmaceuticals; APOLLO ClinicalTrials.gov number, NCT01960348 .).

References

YearCitations

Page 1